July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparing effects of photodynamic therapy in central serous chorioretinopathy: Full-dose versus Half-dose versus Half-dose-half-power
Author Affiliations & Notes
  • Wookyung Park
    Seoul St. Mary's hospital, Seoul, Korea (the Republic of)
  • Mirinae Kim
    Seoul St. Mary's hospital, Seoul, Korea (the Republic of)
  • Rae Young Kim
    Seoul St. Mary's hospital, Seoul, Korea (the Republic of)
  • Young-Hoon Park
    Seoul St. Mary's hospital, Seoul, Korea (the Republic of)
    Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Wookyung Park, None; Mirinae Kim, None; Rae Young Kim, None; Young-Hoon Park, National Research Foundation of Korea (NRF) (F)
  • Footnotes
    Support  Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2016R1A6A1A03010528)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4085. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wookyung Park, Mirinae Kim, Rae Young Kim, Young-Hoon Park; Comparing effects of photodynamic therapy in central serous chorioretinopathy: Full-dose versus Half-dose versus Half-dose-half-power. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4085.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare effects of full-dose, half-dose, and half-dose-half-power photodynamic therapy (PDT) in central serous chorioretinopathy (CSC).

Methods : This retrospective study enrolled patients with CSC who received full-dose (verteporfin 6 mg/m2), half- dose (verteporfin 3 mg/m2) and half-dose-half-power (verteporfin 3 mg/m2 and light energy reduced to 25 J/cm2) PDT. We measured visual acuity, subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) thickness, and choroidal vascularity index (CVI) before and 3months after PDT.

Results : 43 eyes (42 patients) were analyzed. Full-dose and half-dose groups showed improved vision (P = 0.023, 0.004, respectively), but half-dose-half power group was not significantly improved (P = 0.254). SFCT in all three groups were significantly decreased (P = 0.005, 0.004, 0.002, respectively). SRF thicknesses in full-dose and half-dose groups showed significant decreases (P = 0.005, < 0.001, respectively). Half-dose-half-power group demonstrated the decrease but it was not statistically significant (P = 0.084). CVI were decreased in full-dose and half-dose groups (all P = 0.005). However, in the half-dose-half-power group, CVI was increased (P = 0.003).

Conclusions : Full-dose and half-dose PDT were both effective in CSC treatment. Half-dose PDT can be considered regarding complications. The effect of half-dose-half-power PDT was less clear than other two protocols.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×